Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization ...

Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $98.0, a ...

HC Wainwright reiterated their buy rating on shares of Ultragenyx Pharmaceutical (NASDAQ:RARE – Free Report) in a report ...

Last week, you might have seen that Ultragenyx Pharmaceutical Inc. ( NASDAQ:RARE ) released its yearly result to ...

RARE reports mixed fourth-quarter results, as earnings miss estimates while revenues beat the same. Product sales increase year over year.

Ultragenyx (RARE) announced the FDA has accepted for review the Biologics License Application, or BLA, seeking accelerated approval for UX111 ...

Canaccord analyst Whitney Ijem raised the firm’s price target on Ultragenyx (RARE) to $136 from $121 and keeps a Buy rating on the shares. The ...

Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Free Report) had its price objective hoisted by Canaccord Genuity Group from $121.00 to $136.00 in a report released on Tuesday,Benzinga reports.

Ultragenyx has demonstrated solid financial performance in recent quarters, beating revenue expectations and raising guidance. In its most recent quarter, the company reported revenue of $147 ...

Discover how Ultragenyx achieved 29% revenue growth in 2024, set 2025 guidance at $640M-$670M, and advanced clinical progress toward profitability by 2027.